POGO

  • Staff List
  • Contact Us

Main menu

Skip to primary content
Skip to secondary content
  • About Us
    • Our Mission and Vision
    • Childhood Cancer Care Plan
    • POGO Land Acknowledgement
    • Diversity, Equity, Inclusion
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • Accessibility
    • Reports
    • Newsroom
    • Job Opportunities
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO Virtual Education
    • Indigenous Resource Guide
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • POGO Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

Research & Data

POGO > Research & Data > POGO Research Unit > Research Funding > POGO Fellows
icon-facebook

POGO Fellows

POGO proudly announces its Fellows and their winning projects.

Noelle M. Cullinan, MD
Catherine Goudie, MD, FRCPC
Iska Moxon-Emre, MSc, MA, PhD(c)
Priya Patel, MD, MSc(c)


Noelle M. Cullinan, MD

Project Title: Validation of a Prediction Tool for Cancer Predisposition Syndromes and Estimation of the Potential Genetic Predisposition to Subsequent Malignant Neoplasms in Pediatric Cancer Survivors: An Ontario Population-Based Nested Case-Control Study

Principal Investigator: Noelle M. Cullinan, MD

Co-Principal Investigator:  Paul Nathan, MD

Co-Investigators Catherine Goudie, MD; Jason Pole, PhD; Anita Villani, MD, MSc; David Malkin, MD

Project Summary: Improvements in pediatric oncology care over time have led to increasing survival rates. A significant proportion of childhood cancer survivors (CCS) develop subsequent malignancies. 10-30% of children with cancer have an underlying cancer predisposition syndrome (CPS) that increases their risk of developing subsequent cancers. This project aims to validate the McGill Interactive Pediatric Oncogenetic Guidelines (MIPOGG) as a prediction tool for CPSs and subsequent cancers, and estimate the potential genetic contribution to the development of subsequent cancers in CCS.

Impact/Relevance: Detection of a CPS, or increased risk of subsequent cancers, in a child with a first cancer is vital for optimizing treatment strategies, enrolling in surveillance protocols and improving patient outcomes through earlier detection and treatment of subsequent cancers. When validated, the MIPOGG will be a powerful resource for those who care for children with cancer.

Awarded: $55,000



Catherine Goudie, MD, FRCPC

Project Title: Identifying Children at Increased Risk for a Cancer Predisposition Syndrome: The McGill Interactive Pediatric Oncogenetic Guidelines (MIPOGG Study)

Principal Investigator: Dr. William Foulkes 

Co-Principal Investigator: Dr. David Malkin

Project Summary: Many genetic diseases are known to increase the risk of cancer development in children. A childhood cancer can be the first sign of a cancer predisposition syndrome (a genetic disorder that heightens the risk of developing cancers throughout life). Too often, the association between the cancer and a syndrome goes unrecognized by doctors. The team’s project is to develop a tool called the McGill Interactive Pediatric Oncogenetic Guidelines (MIPOGG) which will provide doctors with tumor-specific algorithms that will identify children at increased risk of having a cancer predisposition syndrome upon a new diagnosis of cancer. No such algorithms exist for children in the medical literature. At the moment, the team created 40/65 tumor algorithms which need to be validated.

Impact/Relevance: Ultimately, the goal of this electronic cancer genetic referral guideline is to give children with a cancer predisposition syndrome and their families the opportunity to be noticed, diagnosed, and treated appropriately. The MIPOGG will also serve as a valuable educational tool for medical professionals.

Awarded: One year Clinician Scholar Award, 2017

Recognition/Honours:
On October 13th, Dr. Goudie presented the MIPOGG study and the preliminary validation process in a poster discussion session at the 49th Congress of the International Society of Pediatric Oncology held in Washington (SIOP). Her research was awarded “Best Poster Discussion” in the non-brain solid tumor category. This project is gaining wide interest from many clinicians and researchers.


Iska Moxon-Emre, MSc, MA, PhD (c)

Project Title: Emotional difficulties in survivors of paediatric brain tumors; a neurobiological perspective

Principal Investigator: Dr. Donald Mabbott

Project Summary: This project will focus on emotional problems, such as anxiety and depression experienced by brain tumour survivors, and will relate these difficulties to structural damage in brain regions important for emotions.

Impact/Relevance: Findings from this study could lead to an increase in emotional monitoring and support for survivors of brain tumours. It could also highlight the importance of protecting brain structures that control emotions from cranial radiation. Together, these intervention and preventative strategies could significantly reduce emotional difficulties experienced by children treated with cranial radiation for brain tumours, and ultimately increase their quality of life.

Awarded: Three-year PhD Fellowship, 2015

Outcomes:

Moxon-Emre I, Bouffet E, Taylor M, Laperriere N, Sharpe M, Laughlin S et al. Vulnerability of white matter to insult during childhood: evidence from patients treated for medulloblastoma. Journal of Neurosurgery: Pediatrics. 2016: 1-12.


Priya Patel, BScPhm, PharmD, RPh

Project Title: Relative bioavailability of an extemporaneous oral suspension of aprepitant in children

Principal Investigator: Dr. Lee Dupuis

Qualified Investigator: Dr. Paul Nathan

Co-Investigators: Ms. Sue Zupanec, Ms. Jocelyne Volpe, Mr. Scott Walker

Project Summary: Nausea and vomiting are distressing side effects of chemotherapy. Aprepitant is one of the most effective medicines to prevent chemotherapy-induced vomiting. Aprepitant is only available as a capsule. So, children who cannot swallow capsules cannot benefit from this medicine. Pharmacists can use aprepitant capsules to make an oral liquid form of aprepitant. But, we do not know how well this form is absorbed into the bloodstream. This study will compare the absorption of the oral liquid aprepitant to the capsule in healthy adult volunteers. Given that the absorption and metabolism of aprepitant in children is similar to adults by one year of age, the results of this study will be applicable to children.

Impact/Relevance: If the absorption pattern of oral liquid aprepitant and the capsule are similar, children who cannot swallow capsules and who are receiving chemotherapy will have access to a medicine known to improve control of chemotherapy-induced nausea and vomiting.

Awarded: One-year Clinician Scholar Fellowship, 2016

In This Section

  • POGO Research Unit
    • Research Funding
      • Project Funding Grants
      • Past Seed Grant Recipients
      • POGO Fellows
    • Research Impact
  • POGONIS – Childhood Cancer Database
  • Data Reports

Donate

Blog

Education Portal
Survivor Conference
All Categories

Categories

Newsletter Sign-Up

Please leave this field empty

@POGO4Kids

January 30, 2023

We’re excited to have @TD_Canada as a POGO PJ Party sponsor! Thank you for the support to help ensure everyone affected by #childhoodcancer has access to the best care and support. Learn more here: http://pogopjparty.com #POGOPJParty

Reply on Twitter 1620130019392774144 Retweet on Twitter 1620130019392774144 Like on Twitter 1620130019392774144 3 Twitter 1620130019392774144

Follow @POGO4Kids

Quick Links

  • For Professionals
    • Read Cancer Care Plan
    • Review our Guidelines
    • Request Research Data
  • Families & Kids
    • Get POGO AfterCare
    • Meet with a POGO Nurse
    • Get Care Closer to Home
  • For Survivors
    • Find Local Resources
    • Set Goals for your Future
    • Educate Yourself
  • Get Involved
    • Host an Event for POGO
    • Volunteer with POGO
    • Partner with POGO
  • About Us
    • Our Mission and Vision
    • Childhood Cancer Care Plan
    • POGO Land Acknowledgement
    • Diversity, Equity, Inclusion
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • Accessibility
    • Reports
    • Newsroom
    • Job Opportunities
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO Virtual Education
    • Indigenous Resource Guide
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • POGO Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

©2022 Pediatric Oncology Group of Ontario

480 University Avenue, Suite 1014 | Toronto, Ontario, M5G 1V2, Canada | Charitable Registration Number: 871067245RR0001 |
1-855-FOR POGO (367-7646) | Contact Us | Website Privacy Policy | Website Disclaimer | Satellite Manual Disclaimer |